273 related articles for article (PubMed ID: 37217614)
1. Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment.
Azimnasab-Sorkhabi P; Soltani-Asl M; Yoshinaga TT; Zaidan Dagli ML; Massoco CO; Kfoury Junior JR
Mol Biol Rep; 2023 Jul; 50(7):6133-6145. PubMed ID: 37217614
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.
Ball HJ; Yuasa HJ; Austin CJ; Weiser S; Hunt NH
Int J Biochem Cell Biol; 2009 Mar; 41(3):467-71. PubMed ID: 18282734
[TBL] [Abstract][Full Text] [Related]
3. Role of tryptophan metabolism in cancers and therapeutic implications.
Liu XH; Zhai XY
Biochimie; 2021 Mar; 182():131-139. PubMed ID: 33460767
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases.
Heidari F; Ramezani A; Erfani N; Razmkhah M
Int Rev Immunol; 2022; 41(3):346-363. PubMed ID: 33118843
[TBL] [Abstract][Full Text] [Related]
6. Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review.
Wells G; Kennedy PT; Dahal LN
Front Immunol; 2021; 12():651687. PubMed ID: 33777052
[No Abstract] [Full Text] [Related]
7. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
8. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
9. Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia.
Sobash PT; Kolhe R; Karim NA; Guddati AK; Jillella A; Kota V
Future Oncol; 2020 Dec; 16(36):3085-3094. PubMed ID: 32976029
[TBL] [Abstract][Full Text] [Related]
10. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
11. IDO/kynurenine pathway in cancer: possible therapeutic approaches.
Abd El-Fattah EE
J Transl Med; 2022 Aug; 20(1):347. PubMed ID: 35918736
[TBL] [Abstract][Full Text] [Related]
12. Substrate Oxidation by Indoleamine 2,3-Dioxygenase: EVIDENCE FOR A COMMON REACTION MECHANISM.
Booth ES; Basran J; Lee M; Handa S; Raven EL
J Biol Chem; 2015 Dec; 290(52):30924-30. PubMed ID: 26511316
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
15. Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism.
Trézéguet V; Fatrouni H; Merched AJ
Cells; 2021 Dec; 10(12):. PubMed ID: 34943977
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
18. Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
Matsuda A; Hata A; Tanaka A; Matsuda H
Res Vet Sci; 2021 Jul; 137():159-162. PubMed ID: 33984619
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
